Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Paris – page 186

2 598 clinical trials in Paris, France across 36 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Paris at a glance
2 598
clinical trials
  • Research sites36
Type of trial
Recruitment status
Quick filters

2 598 trials in Paris

Open in trial search

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Colorectal cancer metastatic

Not recruiting

Study Comparing Regorafenib and Regorafenib-Irinotecan Combination for Patients with Metastatic Colorectal Cancer After Standard Treatments Have Failed

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Institut Regional Du Cancer De Montpellier

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Tolerability of Teprotumumab for Patients with Thyroid Eye Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Rectal cancer

Not recruiting

Study on Chemotherapy and Pelvic Reirradiation for Patients with Recurrent Rectal Cancer Using Irinotecan, Levoleucovorin, Fluorouracil, Oxaliplatin, and Capecitabine

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Oesophageal adenocarcinoma

Not recruiting

Study on FOLFOX and Docetaxel for Patients with Advanced or Metastatic Stomach and Esophagus Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:Fondation Franc.Cancerologie Digestive

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Long-term Safety and Effectiveness of Danicopan with Ravulizumab or Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Small cell lung cancer

Not recruiting

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Pharma Mar S.A.

Hypercholesterolaemia

Not recruiting

Study on Inclisiran and Rosuvastatin for Lowering Cholesterol in Patients with High Cholesterol Levels

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Renal transplant

Not recruiting

Study on Adjusting Enoxaparin Dose for Children with Kidney Transplants to Prevent Blood Clots

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Enoxaparin Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Acute myeloid leukaemia

Not recruiting

Study of Pivekimab Sunirine for Adults with CD123-positive Acute Myeloid Leukemia and Other CD123-positive Blood Cancers

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pivekimab Sunirine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Tepotinib and Osimertinib for Patients with Advanced or Metastatic Lung Cancer Resistant to Osimertinib Therapy

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Merck Healthcare KGaA

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Paris

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma and endometrial cancer, evaluating innovative treatment combinations and survival outcomes.

  • Advanced cancer therapies
  • Combination treatments
  • Survival outcome assessment
02 Metabolic Disorders

Clinical investigations targeting Type 1 Diabetes and obesity, with novel therapeutic approaches using tirzepatide for improved glycemic control.

  • Diabetes management
  • Weight control
  • Metabolic health
03 Infectious Diseases

Innovative vaccine trials for COVID-19, influenza, and cytomegalovirus, exploring both intranasal and injectable delivery methods.

  • Vaccine development
  • Immunogenicity studies
  • Prevention strategies
04 Neurological Conditions

Advanced research in multiple sclerosis and Alzheimer's disease, utilizing cutting-edge imaging techniques to study neuroinflammation and synaptic density.

  • Brain imaging
  • Neurodegenerative diseases
  • Disease progression
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.